Ascendis Pharma A/S (NASDAQ:ASND) Stock Price Target Raised at Cantor Fitzgerald

Ascendis Pharma A/S (NASDAQ:ASND) had its price objective upped by stock analysts at Cantor Fitzgerald from $300.00 to $315.00 in a research note issued to investors on Friday, Benzinga reports. The brokerage currently has an “overweight” rating on the biotechnology company’s stock. Cantor Fitzgerald‘s target price suggests a potential upside of 17.95% from the stock’s current price.

ASND has been the subject of a number of other reports. TD Cowen restated a “buy” rating on shares of Ascendis Pharma A/S in a report on Thursday, September 10th. Raymond James Financial lowered shares of Ascendis Pharma A/S from a “strong-buy” rating to an “outperform” rating and set a $287.00 price objective on the stock. in a report on Tuesday, September 15th. Morgan Stanley cut their price objective on shares of Ascendis Pharma A/S from $275.00 to $273.00 and set an “overweight” rating on the stock in a research report on Tuesday, September 1st. Stifel Nicolaus decreased their target price on Ascendis Pharma A/S from $328.00 to $326.00 and set a “buy” rating for the company in a research report on Monday, August 31st. Finally, Bank of America dropped their price target on Ascendis Pharma A/S from $306.00 to $304.00 and set a “buy” rating on the stock in a research note on Monday, August 31st. Nineteen investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $306.25.

Ascendis Pharma A/S Stock Performance

NASDAQ:ASND opened at $267.07 on Friday. The company has a fifty day moving average of $242.58 and a 200-day moving average of $239.65. The firm has a market capitalization of $16.66 billion, a P/E ratio of 20.72 and a beta of 0.40. The company has a quick ratio of 2.32, a current ratio of 2.99 and a debt-to-equity ratio of 0.27. Ascendis Pharma A/S has a twelve month low of $188.07 and a twelve month high of $282.15.

Ascendis Pharma A/S (NASDAQ:ASND) last released its earnings results on Friday, August 14th. The biotechnology company reported $1.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.71 by ($0.68). The company had revenue of $387.22 million for the quarter, compared to analyst estimates of $376.75 million. Ascendis Pharma A/S had a net margin of 70.99% and a return on equity of 32.54%. As a group, sell-side analysts anticipate that Ascendis Pharma A/S will post 3.43 EPS for the current year.

Insider Transactions at Ascendis Pharma A/S

In related news, SVP Mads Bodenhoff sold 3,000 shares of Ascendis Pharma A/S stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $270.19, for a total value of $810,570.00. Following the completion of the sale, the senior vice president owned 3,000 shares of the company’s stock, valued at approximately $810,570. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 40.00% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Perceptive Advisors LLC grew its holdings in shares of Ascendis Pharma A/S by 41.6% during the first quarter. Perceptive Advisors LLC now owns 1,531,421 shares of the biotechnology company’s stock valued at $350,282,000 after buying an additional 450,000 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in shares of Ascendis Pharma A/S in the 1st quarter worth about $26,837,000. Troluce Capital Advisors LLC bought a new position in Ascendis Pharma A/S in the 1st quarter valued at about $22,782,000. Sapient Capital LLC bought a new position in Ascendis Pharma A/S in the 2nd quarter valued at about $24,581,000. Finally, Frazier Life Sciences Management L.P. lifted its position in Ascendis Pharma A/S by 68.9% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 225,155 shares of the biotechnology company’s stock valued at $60,053,000 after acquiring an additional 91,822 shares in the last quarter.

Key Ascendis Pharma A/S News

Here’s some of the latest news about ASND:

• Positive Sentiment: Ascendis reported Q3 product revenue of €366 million, up 89% year over year, led by YORVIPATH at €291 million. The company also reported better-than-expected earnings and revenue, and said it expects at least €600 million in operating cash flow for the full year. Ascendis Pharma Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Regulatory progress may add to the growth outlook: European regulators recommended marketing authorization for TransCon CNP, with a European Commission decision expected in Q4 2026 and a planned first launch in Germany in Q1 2027. Ascendis Pharma Reports Third Quarter 2026 Financial Results
• Neutral Sentiment: The company granted 28,030 employee warrants, which may have a modest dilutive effect. Ascendis Pharma Grants 28,030 Employee Warrants

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a biopharmaceutical company headquartered in Denmark that develops medicines for rare diseases, with a focus on endocrinology. Founded in 2006, the company uses its TransCon technology platform to design therapies intended to provide sustained delivery of medicines. Its commercial products include SKYTROFA (lonapegsomatropin), a once-weekly growth hormone treatment for children with growth hormone deficiency, and YORVIPATH (palopegteriparatide), a treatment for adults with hypoparathyroidism.